Reviva Pharmaceuticals Holdings Stock EBITDA
| RVPH Stock | USD 1.77 0.01 0.56% |
Reviva Pharmaceuticals Holdings fundamentals help investors to digest information that contributes to Reviva Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Reviva Stock. The fundamental analysis module provides a way to measure Reviva Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Reviva Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -35.6 T | -33.8 T |
Reviva | EBITDA |
Reviva Pharmaceuticals Holdings Company EBITDA Analysis
Reviva Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Reviva Pharmaceuticals EBITDA | (39.5 T) |
Most of Reviva Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reviva Pharmaceuticals Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Reviva EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Reviva Pharmaceuticals is extremely important. It helps to project a fair market value of Reviva Stock properly, considering its historical fundamentals such as EBITDA. Since Reviva Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Reviva Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Reviva Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Reviva Ebitda
Ebitda |
|
According to the company disclosure, Reviva Pharmaceuticals Holdings reported earnings before interest,tax, depreciation and amortization of (39.5 Trillion). This is 4502287.43% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The ebitda for all United States stocks is significantly higher than that of the company.
Reviva EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Reviva Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Reviva Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reviva Pharmaceuticals by comparing valuation metrics of similar companies.Reviva Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Reviva Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Reviva Pharmaceuticals from analyzing Reviva Pharmaceuticals' financial statements. These drivers represent accounts that assess Reviva Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Reviva Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 26.8M | 42.7M | 82.9M | 122.6M | 110.3M | 115.8M | |
| Enterprise Value | 18.0M | 13.1M | 64.4M | 99.2M | 89.3M | 93.7M |
Reviva Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Reviva Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Reviva Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Reviva Pharmaceuticals' value.| Shares | State Street Corp | 2024-09-30 | 71.4 K | Susquehanna International Group, Llp | 2024-09-30 | 63.2 K | H D Vest Advisory Services | 2024-09-30 | 60 K | Northern Trust Corp | 2024-09-30 | 57.7 K | Sound Income Strategies | 2024-09-30 | 30 K | Two Sigma Investments Llc | 2024-09-30 | 21.4 K | Emc Capital Management(tx) | 2024-09-30 | 18.4 K | Virtu Financial Llc | 2024-09-30 | 14.3 K | Two Sigma Securities, Llc | 2024-09-30 | 13.9 K | Armistice Capital, Llc | 2024-09-30 | 3.2 M | Millennium Management Llc | 2024-09-30 | 1.8 M |
Reviva Fundamentals
| Return On Equity | -17.95 | ||||
| Return On Asset | -2.34 | ||||
| Current Valuation | 76.97 M | ||||
| Shares Outstanding | 46.58 M | ||||
| Shares Owned By Insiders | 14.78 % | ||||
| Shares Owned By Institutions | 30.06 % | ||||
| Number Of Shares Shorted | 5.64 M | ||||
| Price To Book | 8.35 X | ||||
| EBITDA | (39.5 T) | ||||
| Net Income | (39.26 M) | ||||
| Cash And Equivalents | 23.19 M | ||||
| Cash Per Share | 1.13 X | ||||
| Total Debt | 17.98 M | ||||
| Current Ratio | 6.72 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | (28.32 M) | ||||
| Short Ratio | 19.04 X | ||||
| Earnings Per Share | (1.07) X | ||||
| Target Price | 12.57 | ||||
| Number Of Employees | 15 | ||||
| Beta | -0.055 | ||||
| Market Capitalization | 82.91 M | ||||
| Total Asset | 23.7 M | ||||
| Retained Earnings | (134.35 M) | ||||
| Working Capital | 6.53 M | ||||
| Net Asset | 23.7 M |
About Reviva Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Reviva Pharmaceuticals Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reviva Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reviva Pharmaceuticals Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Reviva Pharmaceuticals Piotroski F Score and Reviva Pharmaceuticals Altman Z Score analysis. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.